Selexipag (BioDeep_00000183765)
human metabolite blood metabolite
代谢物信息卡片
2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-methanesulfonylacetamide
化学式: C26H32N4O4S (496.2144152)
中文名称: 赛乐西帕
谱图信息:
最多检出来源 Mus musculus(blood) 50%
分子结构信息
SMILES: CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
InChI: InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)
描述信息
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
C78568 - Prostaglandin Analogue
同义名列表
10 个代谢物同义名
2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-methanesulfonylacetamide; 2-(4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide; 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-methanesulfonylacetamide; ACT 293987; ACT-293987; Selexipag; Uptravi; NS 304; NS-304; lex
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:90844
- PubChem: 9913767
- HMDB: HMDB0258215
- DrugBank: DB11362
- ChEMBL: CHEMBL238804
- Wikipedia: Selexipag
- chemspider: 8089417
- CAS: 475086-01-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Xiaoyi Hu, Ping Yuan, Jun Chen, Shang Wang, Hui Zhao, Yaqin Wei, Jiaqi Fu, Fadong Chen, Hongyun Ruan, Wei Zhang, Yanli Zhou, Qiqi Wang, Xiaoling Xu, Kefu Feng, Jianzhou Guo, Sugang Gong, Ruifeng Zhang, Qinhua Zhao, Lan Wang. Impact of different sequential triple oral combination therapies based selexipag on outcomes in pulmonary arterial hypertension.
Clinical cardiology.
2024 Feb; 47(2):e24245. doi:
10.1002/clc.24245. [PMID: 38402556] - Naoki Katayama, Keiichi Odagiri, Akio Hakamata, Chiaki Kamiya, Shinya Uchida, Shimako Tanaka, Naoki Inui, Noriyuki Namiki, Koichiro Tatsumi, Hiroshi Watanabe. Clinical evaluation of drug-drug interactions between the cytochrome P450 substrates selexipag and clopidogrel in Japanese volunteers.
British journal of clinical pharmacology.
2021 04; 87(4):1903-1911. doi:
10.1111/bcp.14579. [PMID: 32997809] - Son Hai Vu, Alisha Wehdnesday Bernardo Reyes, Tran Xuan Ngoc Huy, Wongi Min, Hu Jang Lee, Hyun-Jin Kim, John Hwa Lee, Suk Kim. Prostaglandin I2 (PGI2) inhibits Brucella abortus internalization in macrophages via PGI2 receptor signaling, and its analogue affects immune response and disease outcome in mice.
Developmental and comparative immunology.
2021 02; 115(?):103902. doi:
10.1016/j.dci.2020.103902. [PMID: 33091457] - Keiichi Kuwano, Keiji Kosugi, Chiaki Fuchikami, Shunji Funaki. [Pharmacological characteristics and clinical study results of Selexipag (Uptravi® tablets), a selective prostacyclin receptor agonist].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica.
2021; 156(3):178-186. doi:
10.1254/fpj.20092. [PMID: 33952848] - Lene Nygaard Axelsen, Italo Poggesi, Freya Rasschaert, Juan Jose Perez Ruixo, Shirin Bruderer. Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects.
British journal of clinical pharmacology.
2021 01; 87(1):119-128. doi:
10.1111/bcp.14365. [PMID: 32415684] - Saili Xie, Lu Shi, Jingjing Chen, Ren-Ai Xu, Xuemei Ye. Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method.
Journal of pharmaceutical and biomedical analysis.
2020 Oct; 190(?):113496. doi:
10.1016/j.jpba.2020.113496. [PMID: 32768890] - E V Karelkina, N S Goncharova, M A Simakova, O M Moiseeva. [Experience with Selexipag to Treat Pulmonary Arterial Hypertension].
Kardiologiia.
2020 Mar; 60(4):36-42. doi:
10.18087/cardio.2020.4.n1026. [PMID: 32394855] - Carmela Gnerre, Jérôme Segrestaa, Swen Seeland, Päivi Äänismaa, Thomas Pfeifer, Stephane Delahaye, Ruben de Kanter, Tomohiko Ichikawa, Tetsuhiro Yamada, Alexander Treiber. The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag.
Xenobiotica; the fate of foreign compounds in biological systems.
2018 Jul; 48(7):704-719. doi:
10.1080/00498254.2017.1357088. [PMID: 28737453] - Tomohiko Ichikawa, Tetsuhiro Yamada, Alexander Treiber, Carmela Gnerre, Kiyoko Nonaka. Pharmacokinetics of the selective prostacyclin receptor agonist selexipag in rats, dogs and monkeys.
Xenobiotica; the fate of foreign compounds in biological systems.
2018 Feb; 48(2):186-196. doi:
10.1080/00498254.2017.1294277. [PMID: 28277164] - Margaux Boehler, Shirin Bruderer, Ivan Ulč, Jasper Dingemanse. Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.
European journal of drug metabolism and pharmacokinetics.
2018 Feb; 43(1):115-120. doi:
10.1007/s13318-017-0424-z. [PMID: 28639216] - Shirin Bruderer, Marc Petersen-Sylla, Margaux Boehler, Tatiana Remeňová, Atef Halabi, Jasper Dingemanse. Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.
British journal of clinical pharmacology.
2017 12; 83(12):2778-2788. doi:
10.1111/bcp.13379. [PMID: 28715853] - Pierre-Eric Juif, Margaux Boehler, Yves Donazzolo, Shirin Bruderer, Jasper Dingemanse. A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.
European journal of clinical pharmacology.
2017 Sep; 73(9):1121-1128. doi:
10.1007/s00228-017-2282-7. [PMID: 28639119] - Priska Kaufmann, Hans G Cruz, Andreas Krause, Ivan Ulč, Atef Halabi, Jasper Dingemanse. Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.
British journal of clinical pharmacology.
2016 08; 82(2):369-79. doi:
10.1111/bcp.12963. [PMID: 27062188] - Sri N Batchu, Syamantak Majumder, Bridgit B Bowskill, Kathryn E White, Suzanne L Advani, Angela S Brijmohan, Youan Liu, Kerri Thai, Paymon M Azizi, Warren L Lee, Andrew Advani. Prostaglandin I2 Receptor Agonism Preserves β-Cell Function and Attenuates Albuminuria Through Nephrin-Dependent Mechanisms.
Diabetes.
2016 05; 65(5):1398-409. doi:
10.2337/db15-0783. [PMID: 26868296] - Priska Kaufmann, Séverine Niglis, Shirin Bruderer, Jérôme Segrestaa, Päivi Äänismaa, Atef Halabi, Jasper Dingemanse. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.
British journal of clinical pharmacology.
2015 Oct; 80(4):670-7. doi:
10.1111/bcp.12650. [PMID: 25851691] - Tetsuo Asaki, Keiichi Kuwano, Keith Morrison, John Gatfield, Taisuke Hamamoto, Martine Clozel. Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
Journal of medicinal chemistry.
2015 Sep; 58(18):7128-37. doi:
10.1021/acs.jmedchem.5b00698. [PMID: 26291199] - Priska Kaufmann, Kaori Okubo, Shirin Bruderer, Tim Mant, Tetsuhiro Yamada, Jasper Dingemanse, Hideya Mukai. Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2015 Jun; 15(3):195-203. doi:
10.1007/s40256-015-0117-4. [PMID: 25850750] - Matthias Hoch, Borje Darpo, Tatiana Remenova, Randall Stoltz, Meijian Zhou, Priska Kaufmann, Shirin Bruderer, Jasper Dingemanse. A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist.
Drug design, development and therapy.
2015; 9(?):175-85. doi:
10.2147/dddt.s75565. [PMID: 25552906] - Shirin Bruderer, Noémie Hurst, Priska Kaufmann, Jasper Dingemanse. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects.
Pharmacology.
2014; 94(3-4):148-56. doi:
10.1159/000367630. [PMID: 25277144] - N N Orie, A Ledwozyw, D J Williams, B J Whittle, L H Clapp. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins.
Prostaglandins & other lipid mediators.
2013 Oct; 106(?):1-7. doi:
10.1016/j.prostaglandins.2013.07.003. [PMID: 23872196] - Akio Nakamura, Tetsuhiro Yamada, Tetsuo Asaki. Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist.
Bioorganic & medicinal chemistry.
2007 Dec; 15(24):7720-5. doi:
10.1016/j.bmc.2007.08.052. [PMID: 17881233] - Keiichi Kuwano, Asami Hashino, Tetsuo Asaki, Taisuke Hamamoto, Tetsuhiro Yamada, Kaori Okubo, Kenji Kuwabara. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug.
The Journal of pharmacology and experimental therapeutics.
2007 Sep; 322(3):1181-8. doi:
10.1124/jpet.107.124248. [PMID: 17545310] - M Negishi, Y Sugimoto, A Ichikawa. Prostanoid receptors and their biological actions.
Progress in lipid research.
1993; 32(4):417-34. doi:
10.1016/0163-7827(93)90017-q. [PMID: 8309950]